Indivior Pharmaceuticals (INDV) EBT Margin (2024 - 2026)

Indivior Pharmaceuticals' EBT Margin history runs 3 years deep, the most recent figure standing at 36.28% for Q1 2026.

• On a quarterly basis, EBT Margin rose 1410.0% year-over-year to 36.28% in Q1 2026; TTM through Mar 2026 was 22.85%, a 2234.0% increase from a year earlier, with the FY2025 full-year figure at 19.29%, up 1761.0% from the prior year.
• EBT Margin grew to 36.28% in Q1 2026 per INDV's latest filing, from 22.63% in the prior quarter.
• Across five years, EBT Margin topped out at 36.28% in Q1 2026 and bottomed at 40.47% in Q2 2024.
• The 3-year median for EBT Margin is 20.53% (2025), against an average of 13.46%.
• Biggest YoY gain for EBT Margin was 6100 bps in 2025; the steepest drop was 352 bps in 2025.
• Year by year, EBT Margin stood at 12.71% in 2024, then surged by 78 bps to 22.63% in 2025, then soared by 60 bps to 36.28% in 2026.
• Per Business Quant, the three latest INDV EBT Margin figures stand at 36.28% (Q1 2026), 22.63% (Q4 2025), and 11.78% (Q3 2025).